Competition Law Update: SAMR Fines Foreign Company for Gun-Jumping Violation — Key Takeaways

Date:

Share post:

Competition Law Update: SAMR Fines Foreign Company for Gun-Jumping Violation — Key Takeaways

On 20 March 2025, the State Administration for Market Regulation (SAMR; 国家市场监督管理总局, Guójiā Shìchǎng Jiāndū Guǎnlǐ Zǒngjú) imposed a fine of ¥4.2 million (approximately US$580,000) on a German industrial machinery group for completing a transaction — the acquisition of a controlling stake in a Suzhou-based sensor manufacturer — before obtaining antitrust clearance, a practice known as “gun-jumping” (抢跑, qiǎngpǎo). This marks the fifth gun-jumping penalty issued by SAMR in the past 24 months and sends a clear signal that foreign companies operating in China must treat pre-merger notification (经营者集中申报, jīngyíngzhě jízhōng shēnbào) as a binding prerequisite, not an optional formality.

The Case: SAMR Fines a German Machinery Group for Gun-Jumping

The German buyer, a global leader in automation components, executed a share purchase agreement in September 2024 to acquire 67% of a Suzhou-based sensor firm. The combined annual revenue of both parties in China exceeded ¥1.8 billion in the 2023 fiscal year, triggering the mandatory notification threshold under Article 21 of China’s Anti-Monopoly Law (反垄断法, fǎnlǒngduàn fǎ). Despite being advised by its legal counsel to file with SAMR, the buyer closed the transaction 48 days after signing — well before receiving SAMR’s clearance decision — on the grounds that “integration could not wait.” SAMR’s investigation, launched after a competitor’s tip-off in November 2024, determined that the deal was implemented without approval. The fine of ¥4.2 million represents 0.23% of the parties’ combined turnover in China for the preceding fiscal year, the maximum percentage currently allowed under the revised AML for non-cartel violations.

Why Gun-Jumping Matters Under China’s AML

Gun-jumping undermines the regulatory purpose of pre-merger review, which is to prevent transactions that may eliminate or restrict competition before SAMR has a chance to assess their impact. Under the revised Anti-Monopoly Law, effective August 2022, SAMR has significantly increased enforcement resources: the agency processed 421 merger notifications in 2024 alone, up from 312 in 2022. The average review timeline for Phase I cases is 28 days, while Phase II investigations take 120–180 days. In this German case, had the buyer filed on time, the deal would likely have been cleared within 35 days — a delay the company judged too long for its integration schedule. The cost of that miscalculation: ¥4.2 million in fines, plus reputational damage and potential claims from minority shareholders who now face an uncertain regulatory path forward.

Comparison: SAMR Gun-Jumping Fines (2020–2025)

Year Company (Nationality) Industry Fine (RMB) % of Turnover Days Until Filing
2020 U.S. semiconductor (US) Semiconductor ¥3.5 million 0.15% 73 days
2022 French energy (FR) Energy ¥4.0 million 0.20% 52 days
2023 Japanese automotive (JP) Automotive ¥3.8 million 0.18% 61 days
2024 South Korean chemical (KR) Chemicals ¥4.1 million 0.22% 55 days
2025 German machinery (DE) Industrial machinery ¥4.2 million 0.23% 48 days

The table illustrates a clear upward trend in both the absolute fine amount and the percentage of turnover applied. SAMR’s approach has become more stringent: fines now approach the 0.30% ceiling (the maximum for non-cartel violations) in cases where the buyer was explicitly advised of the notification obligation and chose to close anyway. The German buyer in this case fell into that category, which explains the near-maximum fine.

Key Takeaways for Foreign Companies in China

First, do not assume your transaction falls below the threshold. The filing triggers in China are based on combined turnover of all parties in China (¥400 million for the acquirer and ¥0 for the target, or ¥2 billion combined with at least two parties each having ¥400 million in China). In this case, the German group’s China revenue alone was ¥1.2 billion, and the target’s China revenue was ¥600 million — well above the thresholds. Foreign companies often underestimate the China-specific revenue of their subsidiaries or fail to aggregate turnover across affiliates. Second, integration planning must account for SAMR timelines. The German buyer’s claim that “integration could not wait” would have been an acceptable argument for seeking expedited review (SAMR does offer fast-track for certain transactions), not for closing without clearance. Companies should build a buffer of 45–60 days in deal timetables for SAMR review, with an additional 90 days if a Phase II investigation is possible. Third, non-compliance has severe collateral consequences. Beyond the fine, SAMR can order the unwinding of the transaction — a remedy that can cost millions in legal fees, restructuring, and lost synergies. The SAMR can also impose daily penalty fines for continued non-compliance, and individuals responsible may face personal liability under the revised AML (Article 56).

Three Common Gun-Jumping Pitfalls

Pitfall: Closing a transaction while SAMR review is still pending, believing that approval is “almost certain” and that early integration creates business value. Cost: ¥4.2 million fine in this case, plus legal fees of ¥1.2 million for the investigation, and an estimated ¥8 million in potential deal-unwinding costs if SAMR decides to undo the transaction. Fix: Include a written covenant in the share purchase agreement that closing cannot occur until SAMR issues a clearance decision or the statutory waiting period expires, whichever is later. Never implement any operational integration before clearance — including transferring IP, appointing board members, or sharing competitively sensitive information.
Pitfall: Failing to include China subsidiaries’ turnover when calculating whether the filing threshold is met, especially when the target is an offshore holding company that has an operating subsidiary in China. Cost: This miscalculation led to a four-month investigation delay in a 2022 case involving a French energy group, which had to pay ¥4.0 million fine and lost an estimated ¥15 million in business momentum during the delay. Fix: Use a dedicated China antitrust counsel to prepare the turnover calculation at least two weeks before signing, and include a robust anti-gun-jumping clause (反抢跑条款, fǎn qiǎngpǎo tiáokuǎn) in the acquisition documentation that imposes penalties if either party closes without SAMR clearance.
Pitfall: Signing a deal and then “structuring” it as a phased transaction where only a minority stake is transferred first, believing this avoids the notification requirement. Cost: SAMR can pierce the structure and impose a fine equal to 0.30% of the combined turnover, as happened in the 2023 Japanese automotive case (¥3.8 million fine). If the structure is deemed a sham, the entire transaction may be subject to unwinding. Fix: If the transaction involves any transfer of control — even de facto control through veto rights or board appointments — treat it as notifiable. Seek a pre-filing consultation with SAMR (available at no cost) to confirm whether notification is required before signing.

NEXT STEPS

  1. Review your current deal pipeline for China exposure. If your company is planning any acquisition, joint venture, or asset purchase in China, assess whether the transaction triggers SAMR notification. Use our SAMR Gun-Jumping Risk Assessment Tool to calculate your combined turnover in China and identify red flags.
  2. Build a SAMR clearance timeline into your deal timetable. Add 45–60 days for Phase I review and 120–180 days for Phase II. Do not sign any integration-related agreements — including IT system migration, personnel transfers, or customer notification plans — before clearance. Read our China Merger Control Timeline Guide for detailed milestones.
  3. Engage China-qualified antitrust counsel early. SAMR accepts pre-notification consultations (预申报, yù shēnbào) that can help you avoid filing errors and reduce review time. Schedule a consultation with our partner law firm via SAMR Pre-Merger Notification Assistance to prepare your filing package at least 30 days before signing.

— China Gateway 360 —
Remote China market entry support, built around execution.

Related articles

How a Foreign Biotech Startup Entered China’s Precision Medicine Market: Case Study

How a Foreign Biotech Startup Entered China's Precision Medicine Market: Case Study In 2023, NovaOnco Therapeutics, a US-based AI biotech startup, exe

How Legend Biotech Secured FDA Approval for CAR-T Therapy: Case Study

How Legend Biotech Secured FDA Approval for CAR-T Therapy: A China Biotech Case Study This case study examines how Legend Biotech (传奇生物, Legend Biotec

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study body{font-family:'Segoe UI',Tahoma,Geneva,Verdana,sans-serif;line-height:

How BeiGene Built a Billion-Dollar Biotech in China: Case Study

How BeiGene Built a Billion-Dollar Biotech in China: Case Study How BeiGene Built a Billion-Dollar Biotech in China: Case Study The story of BeiGene's